Expanding the companys pain care portfolio and leveraging its expertise in biologics.

The goal for treatment of chronic pain continues to be potent, long-lasting analgesia that’s tolerable for patients without the prospect of abuse and dependence, said John Leonard, M.D., senior vice president, global development and research, Abbott. NGF blockers have demonstrated the potential to address all of these requirements, making them a promising treatment for chronic pain patients. Related StoriesOne Globe Lab announces collaboration with BenchWise to improve antibody researchCMC Biologics, River Eyesight sign manufacturing contract for Teprotumumab to take care of Grave's OrbitopathyMorphoSys, Immatics partner to build up novel antibody-based therapies against multiple proprietary cancer antigensPain is the number 1 reason people visit a health care provider. There are an estimated 72 million diagnosed chronic pain patients in the U.S.Three fractures occurred following a fall from position height, while the fourth was because of trauma not connected with a fall. Discussion Data from three large, placebo-controlled, randomized trials indicate that the chance of fracture of the subtrochanteric or diaphyseal femur linked to the usage of bisphosphonates was extremely low. Although the point estimates of the relative risk with bisphosphonate use suggested no association, self-confidence intervals were wide because of the few events. Furthermore, in the FLEX trial , despite typically a decade of alendronate use, the risk of fracture of the diaphyseal or subtrochanteric femur was low, with no significant increase among females who continued to get alendronate for a decade, as compared with those that discontinued the drug, again confidence intervals were large although.